(Q39768068)

English

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

0 references

0 references

object named as

Ian D Pavord

8

0 references

Eugene R Bleecker

6

object named as

Eugene R Bleecker

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

author name string

Hector G Ortega

1

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Steven W Yancey

2

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Bhabita Mayer

3

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Necdet B Gunsoy

4

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Oliver N Keene

5

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Christopher E Brightling

7

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

publication date

10 May 2016

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

The Lancet. Respiratory medicine

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

549-556

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Severe asthma: from characteristics to phenotypes to endotypes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting eosinophils in allergy, inflammation and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-IL5 therapy for asthma and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Heterogeneity of asthma according to blood inflammatory patterns

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Mepolizumab treatment in patients with severe eosinophilic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The cost of dichotomising continuous variables

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Utilization and Costs of Severe Uncontrolled Asthma in a Managed-Care Setting.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe exacerbations and decline in lung function in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe adult-onset asthma: A distinct phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2816%2930031-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-2600(16)30031-5

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39768068&oldid=2090116968"